186 related articles for article (PubMed ID: 31680161)
21. Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study.
Jaeger VK; Valentini G; Hachulla E; Cozzi F; Distler O; Airó P; Czirják L; Allanore Y; Siegert E; Rosato E; Matucci-Cerinic M; Caimmi C; Henes J; Carreira PE; Smith V; Del Galdo F; Denton CP; Ullman S; De Langhe E; Riccieri V; Alegre-Sancho JJ; Rednic S; Müller-Ladner U; Walker UA;
Arthritis Rheumatol; 2018 Nov; 70(11):1829-1834. PubMed ID: 29781588
[TBL] [Abstract][Full Text] [Related]
22. Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort.
Hoffmann-Vold AM; Midtvedt Ø; Tennøe AH; Garen T; Lund MB; Aaløkken TM; Andreassen AK; Elhage F; Brunborg C; Taraldsrud E; Molberg Ø
J Rheumatol; 2017 Apr; 44(4):459-465. PubMed ID: 28089974
[TBL] [Abstract][Full Text] [Related]
23. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP.
Gilchrist FC; Bunn C; Foley PJ; Lympany PA; Black CM; Welsh KI; du Bois RM
Genes Immun; 2001 Apr; 2(2):76-81. PubMed ID: 11393660
[TBL] [Abstract][Full Text] [Related]
24. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis.
Ochoa E; Martin JE; Assasi S; Beretta L; Carreira P; Guillén A; Simeón CP; Koumakis E; Dieude P; Allanore Y; García-Hernández FJ; Espinosa G; Castellví I; Trapiella JL; Rodriguez L; González-Gay MÁ; Egurbide MV; Sáez L; Callejas-Rubio JL; Vargas-Hitos JA; Hunzelmann N; Riemekasten G; Witte T; Distler JH; Kreuter A; Lunardi C; Santaniello A; Tan FK; Shiels PG; Herrick A; Worthington J; Vonk MC; Koeleman BP; Radstake TR; Mayes MD; Martin J;
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S31-5. PubMed ID: 26314374
[TBL] [Abstract][Full Text] [Related]
25. Clinical and serological features of systemic sclerosis in a Chinese cohort.
Wang J; Assassi S; Guo G; Tu W; Wu W; Yang L; Xiao R; Zhao Y; Chu H; Liu J; Ma Y; Kim SJ; Jin L; Mayes MD; Zou H; Zhou X
Clin Rheumatol; 2013 May; 32(5):617-21. PubMed ID: 23271609
[TBL] [Abstract][Full Text] [Related]
26. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
Gourh P; Tan FK; Assassi S; Ahn CW; McNearney TA; Fischbach M; Arnett FC; Mayes MD
Arthritis Rheum; 2006 Dec; 54(12):3945-53. PubMed ID: 17133608
[TBL] [Abstract][Full Text] [Related]
27. Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement.
Iniesta Arandia N; Espinosa G; Tolosa Vilella C; Guillén Del Castillo A; Rubio Rivas M; Freire M; Vargas Hitos JA; Todolí Parra JA; Rodríguez Carballeira M; Marín Ballvé A; Colunga Argüelles D; González de Echávarri Pérez de Heredia C; Ortego-Centeno N; Trapiella Martínez L; Pla Salas X; Chamorro AJ; Perales Fraile I; Ruiz Muñoz M; Fernández de la Puebla Giménez RÁ; Madroñero Vuelta AB; Pons Martín Del Campo I; Jiménez Pérez de Heredia I; González García A; Fonollosa Pla V; Simeón Aznar CP;
Clin Exp Rheumatol; 2020; 38 Suppl 125(3):106-114. PubMed ID: 31969223
[TBL] [Abstract][Full Text] [Related]
28. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis.
Minier T; Guiducci S; Bellando-Randone S; Bruni C; Lepri G; Czirják L; Distler O; Walker UA; Fransen J; Allanore Y; Denton C; Cutolo M; Tyndall A; Müller-Ladner U; Matucci-Cerinic M; ;
Ann Rheum Dis; 2014 Dec; 73(12):2087-93. PubMed ID: 23940211
[TBL] [Abstract][Full Text] [Related]
29. Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease.
Gunn J; Pauling JD; McHugh NJ
Clin Rheumatol; 2014 Jun; 33(6):869-71. PubMed ID: 24752346
[TBL] [Abstract][Full Text] [Related]
30. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.
Gourh P; Arnett FC; Assassi S; Tan FK; Huang M; Diekman L; Mayes MD; Reveille JD; Agarwal SK
Arthritis Res Ther; 2009; 11(5):R147. PubMed ID: 19799786
[TBL] [Abstract][Full Text] [Related]
31. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.
Greidinger EL; Flaherty KT; White B; Rosen A; Wigley FM; Wise RA
Chest; 1998 Sep; 114(3):801-7. PubMed ID: 9743170
[TBL] [Abstract][Full Text] [Related]
32. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
Volpinari S; La Corte R; Bighi S; Ravenna F; Prandini N; Lo Monaco A; Trotta F
Rheumatol Int; 2011 Sep; 31(9):1183-8. PubMed ID: 20352228
[TBL] [Abstract][Full Text] [Related]
33. Ethnic influence on disease manifestations and autoantibodies in Chinese-descent patients with systemic sclerosis.
Low AH; Johnson SR; Lee P
J Rheumatol; 2009 Apr; 36(4):787-93. PubMed ID: 19228652
[TBL] [Abstract][Full Text] [Related]
34. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.
Komura K; Yanaba K; Ogawa F; Shimizu K; Takehara K; Sato S
Clin Exp Dermatol; 2008 May; 33(3):329-32. PubMed ID: 18312458
[TBL] [Abstract][Full Text] [Related]
35. Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes.
Tieu A; Chaigne B; Dunogué B; Dion J; Régent A; Casadevall M; Cohen P; Legendre P; Terrier B; Costedoat-Chalumeau N; Le Jeunne C; Mouthon L
Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626223
[TBL] [Abstract][Full Text] [Related]
36. Genomic Risk Score impact on susceptibility to systemic sclerosis.
Bossini-Castillo L; Villanueva-Martin G; Kerick M; Acosta-Herrera M; López-Isac E; Simeón CP; Ortego-Centeno N; Assassi S; ; ; ; ; Hunzelmann N; Gabrielli A; de Vries-Bouwstra JK; Allanore Y; Fonseca C; Denton CP; Radstake TR; Alarcón-Riquelme ME; Beretta L; Mayes MD; Martin J
Ann Rheum Dis; 2021 Jan; 80(1):118-127. PubMed ID: 33004331
[TBL] [Abstract][Full Text] [Related]
37. Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients.
Satoh M; Kuwana M; Ogasawara T; Ajmani AK; Langdon JJ; Kimpel D; Wang J; Reeves WH
J Immunol; 1994 Dec; 153(12):5838-48. PubMed ID: 7989779
[TBL] [Abstract][Full Text] [Related]
38. Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?
Corzo P; Pros A; Martinez-Llorens J; Molina L; Ling SF; Balcells E
Clin Rheumatol; 2018 Dec; 37(12):3365-3371. PubMed ID: 30368639
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of anti-IFI16 autoantibodies in pulmonary arterial hypertension and mortality in patients with systemic sclerosis.
Perurena-Prieto J; Callejas-Moraga EL; Sanz-Martínez MT; Colobran R; Guillén-Del-Castillo A; Simeón-Aznar CP
Med Clin (Barc); 2024 Apr; 162(8):370-377. PubMed ID: 38302398
[TBL] [Abstract][Full Text] [Related]
40. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
Diot E; Giraudeau B; Diot P; Degenne D; Ritz L; Guilmot JL; Lemarié E
Chest; 1999 Sep; 116(3):715-20. PubMed ID: 10492277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
